Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection

Neukam, Karin; Munteanu, Daniela; Haubitz, Sebastian; Mira, José A; Ingiliz, Patrick; Rivero-Juárez, Antonio; Lutz, Thomas; de Los Santos-Gil, Ignacio; Scholten, Stefan; Márquez, Manuel; Rauch, Andri; Rockstroh, Jürgen K.; Pineda, Juan A. (2014). Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. Antiviral therapy, 20(4), pp. 407-413. International Medical Press 10.3851/IMP2921

[img] Text
AVT-14-OA-3380_Neukam_IP2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (759kB) | Request a copy

BACKGROUND IL28B genotype predicts response to treatment against hepatitis C virus (HCV) with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favorable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV/HCV-coinfected patients. METHODS All HIV/HCV genotype 1-coinfected subjects who received TVR/PR for at least 4 weeks were included from populations prospectively followed in 22 centers throughout Germany, Switzerland and Spain. RESULTS Of the 129 subjects included, 38 (29.5%) presented with IL28B genotype CC and 94 (72.9%) were treatment-experienced. Ninety-six (73.8%) patients showed undetectable plasma HCV-RNA at treatment week (W) 4: 30 (78.9%) of the IL28B-CC carriers and 65 (71.4%) of the non-CC carriers (p=0.377). Among treatment-naïve patients, proportions of undetectable HCV-RNA among IL28B-CC versus non-CC carriers were 8/9 (88.9%) versus 3/9 (33.3%, p=0.016) and 14/17 (82.4%) versus 11/18 (61.1%, p=0.164) at W2 and W4. The decrease of HCV-RNA at W2 and W4 was similar among the IL28B carriers. CONCLUSIONS IL28B genotype does not predict W4 response to TVR/PR in HIV/HCV-coinfected patients, regardless of their treatment history. However, there is evidence of an impact on response during the first weeks in treatment-naïve patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Haubitz, Sebastian and Rauch, Andri

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1359-6535

Publisher:

International Medical Press

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

05 Jan 2015 14:23

Last Modified:

19 Oct 2015 11:10

Publisher DOI:

10.3851/IMP2921

PubMed ID:

25470790

BORIS DOI:

10.7892/boris.60908

URI:

https://boris.unibe.ch/id/eprint/60908

Actions (login required)

Edit item Edit item
Provide Feedback